Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Change in YIT’s Investor Relations: Essi Nikitin appointed Vice President, Investor Relations of YIT

YIT Corporation Investor News 12 May 2023 at 10:00 a.m.Essi Nikitin (M.Sc. Econ) has been appointed Vice President, Investor Relations of YIT Corporation as of 4 August, 2023. Essi joins YIT from Musti Group, where she has worked as Head of Investor Relations and Communications. Before joining Musti Group, Essi has been working as a senior advisor of financial communications and investor relations at Miltton. In addition, Essi has worked in various investor relations positions at Sampo plc for over 10 years. Essi will report to CFO Tuomas Mäkipeska.  “I warmly welcome Essi to YIT. Her

UPM Biochemicals further expands distribution network for its new sustainable Renewable Functional Fillers (RFF)

Picture_UPM RFF Distribution Network_May 2023 [Participants at this year’s UPM RFF Distribution Summit in Leuna, Germany.] Participants at this year’s UPM RFF Distribution Summit in Leuna, Germany. (UPM, Helsinki, 12.05.2023 at 10:00 EEST) – UPM Biochemicals  announced today that it has further expanded its distribution network in Europe and Turkey for its UPM BioMotion™ Renewable Functional Fillers (RFF), an innovative new category of bio-based products. This strong distribution partner network expands the reach of RFF into new markets and will

BioStock: Status update from CombiGene's CEO

With the first quarter of the year concluded, CombiGene's CEO Jan Nilsson visited BioStock's studio for a status update on the gene therapy company's project. Nilsson not only talks about the pain project COZY and the epilepsy candidate CG01, but also about the company's financial status.Watch the interview with Jan Nilsson at biostock.se: https://www.biostock.se/en/2023/05/status-update-from-combigenes-ceo/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/

The last day of trading with the warrants of series TO6 in Svenska Aerogel Holding AB is today, May 12, 2023

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, NEW ZEALAND, HONG KONG, JAPAN, SOUTH AFRICA, SOUTH KOREA, BELARUS, RUSSIA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES. PLEASE REFER TO IMPORTANT INFORMATION AT THE END OF THE PRESS RELEASE. Today, May 12, 2023, is the last day of trading with the warrants of series TO6 in Svenska Aerogel Holding AB (“Svenska Aerogel” or “the Company”). The subscription period for

NOTICE OF ANNUAL GENERAL MEETING 2023 IN DANCANN PHARMA A/S

NOTICE OF ANNUAL GENERAL MEETING 2023 IN DANCANN PHARMA A/S The Board of Directors hereby convenes the annual general meeting of DanCann Pharma A/S, CVR-no. 39 42 60 05 (“Company”), to be held on Tuesday, 30 May 2023 at 09:00 am (CET) at DanCann Pharma A/S’ address, Rugvænget 5, 6823 Ansager, Denmark The agenda for the annual general meeting is as follows: 6. `. 1. 1. 1. 1. 1. The chairman’s report on the activities of the Company in the past financial year 2. Adoption of the annual report for 2022

Interim report Q3, 2023

Company Announcement no. 25-23Copenhagen, May 12, 2023 This announcement is a summary and should be read in conjunction with Shape Robotics’ interim report for Q1 2023, published on May 12, 2023. The interim report will be available on the company’s website . Financial highlights Q1, 2023 (Jan-Mar) · The Company has realized a revenue of MDKK 18.9 (Q1 2022 MDKK 7.1), corresponding to a revenue growth of 166% · Contribution Margin amounts to MDKK 6.0 (Q1 2022 MDKK 2.6) · Contribution Margin in % YTD amounts to 31% (Q1 37%) ·

DanCann Pharma A/S publishes Annual Report 2022

COPENHAGEN, Denmark, 12 May 2023 - DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) ("DanCann Pharma" or the "Company"), a Danish company powered by cannabinoids, hereby announce that The Board of Directors and the Chief Executive Officer of DanCann Pharma publishes the annual report of the year 2022. The annual report is available in this press release and on the website of DanCann Pharma.For more information, visit: https://www.dancann.com/investor-relations. About DanCann Pharma A/S DanCann Pharma A/S (SS: DANCAN) (OTCQB: DCPXF) was founded in 2018 and is a Danish biopharmaceutical

NYAB Plc's business review 1 January - 31 March 2023: Accelerating balanced growth

NYAB PlcCOMPANY ANNOUNCEMENT12 May 2023 at 09:45NYAB Plc’s business review 1 January – 31 March 2023: Accelerating balanced growth · Revenue was EUR 39.2 (11.6) million, an increase of 34 percent from pro forma revenue of EUR 29.3 million for the comparison period. · EBITA was EUR -1.2 (-1.3) million, an improvement of 55 percent from pro forma EBITA of EUR -2.2 million for the comparison period. · Order backlog at the end of March was EUR 235.0 (156.3) million, an increase of 50 percent from March 2022. · After the review period, settlement agreement with the City of

ADDvise extends the agreement with Laborie at a value of SEK 48 million

ADDvise Group’s subsidiary Sonesta Medical AB extends the agreement with Laborie Medical Technologies (“Laborie”). The agreement is giving Laborie the right to sell Sonesta Medical’s urology- and gynecology patient positioning equipment and video fluoroscopy tables worldwide, with an exclusive right to distribute in USA and some European countries. Laborie commits to a minimum volume of SEK 48 million. The term of the agreement is two years. The total value of the orders during the term of the agreement is at least SEK 48 million. Laborie is a leading global developer, manufacturer and

Notification of transactions by persons discharging managerial responsibilities and persons closely associated with them

Company Announcement No. 55 -2023 OrderYOYO A/SManagers’ transactions   Copenhagen, May 12, 2023   OrderYOYO A/S has received notification pursuant to article 19 of regulation (EU) no. 596/2014 (the market abuse regulation) of the below transactions related to shares in OrderYOYO A/S made by TJOYY22 ApS, closely associated to CEO Jesper Johansen, who has acquired 1,865 shares in OrderYOYO A/S at an average price of DKK 5 per share.  1. Details of the person discharging managerial responsibilities/person closely associateda) Name

DecideAct closes a contract with The Icelandic Association of Local Authorities

Samband íslenskra sveitarfélaga (The Icelandic Association of Local Authorities) has selected DecideAct to provide expertise for developing its organization and approach to building stronger Strategy Execution Management.The Icelandic Association of Local Authorities is a joint representative of and a forum for cooperation between municipalities under the Local Government Act. The Association represents the interests of municipalities to the Government and other parties both in Iceland and abroad, formulates common policy on individual issues, and therefore works closely with the Government

Valmet chosen as the second most attractive employer by engineering students in Finland

Valmet Oyj’s press release on May 12, 2023 at 9:30 a.m. EESTValmet has been chosen as the second most attractive employer by engineering students in Finland. The ranking was published in Universum’s annual Talent Research, which is the biggest employer survey in Finland. In recent years, Valmet has been actively developing its student and university collaboration in Finland and abroad. The focus has been on developing new trainee programs, establishing a global concept for university cooperation, starting to collaborate with schools to make engineering as a subject more attractive to

XMReality continues to increase sales through partners

XMReality AB has had an established partnership with Viveo since February, which now brings in additional sales of licenses. XMReality and Viveo exhibited together at a property fair in Stockholm in March and one of the companies they met there has now signed a three-year contract with Viveo.Viveo is a Swedish company that packages XMReality as a niche offer for the Swedish property market. The purpose of Viveo's service is to facilitate and streamline the handling of error reports and case management within property management. SG Applications & Management, SGAM, has now signed a three-

OrganoTex launched towards golf retail. Dormy, Sweden's largest golf retail chain, first out through a new collaboration.

OrganoClick's brand OrganoTex and Abacus Sportswear starts a collaboration and together launches the OrganoTex product range to golf retailers. Abacus Sportswear is a well-known golf brand and is the market leader in Sweden in shell clothing and is currently represented in 170 stores and golf shops. Through its own sales force, Abacus will market and sell OrganoTex to all customers within its segment in Sweden. First result of the collaboration is Dormy, Sweden's largest golf retailer, which will launch OrganoTex in selected stores and online in May. "We at Abacus look forward to

Children's party at the book release of "Our Hidden Powers"

Authors Kristina Hagström Ilievska and Gabriella Skog recently released their innovative children's book titled "Our Hidden Powers” that teaches kids about renewable- and geothermal energy. The duo celebrated the book release with a grand event last weekend that attracted attendees from the industry, universities, politics, and environmental debates. The Swedish translation of the book, "Våra hemliga krafter," premiered at the event, adding to the excitement and anticipation of the gathering of over 70 attendees at publisher Mondial’s office in Stockholm, Sweden. Under the

Cereno Scientific shares progress update in the Phase II study with drug candidate CS1 in the rare disease PAH

Cereno Scientific (XSAT: CRNO B), a company developing innovative treatments for common and rare cardiovascular disease, today announced an updated progress report of the Phase II study in pulmonary arterial hypertension (PAH) with drug candidate CS1. The study is proceeding well with currently 16 patients enrolled in the study, 9 patients having received CardioMEMS HF System implantation, 5 patients randomized and in active treatment, and 2 patients having completed the study. Recruitment of the 30 PAH patients to be included in the study is on track and top-line results are anticipated at

Kamux Corporation’s Interim Report for January 1—March 31, 2023: Kamux’s revenue decreased and adjusted operating profit decreased significantly

Kamux Corporation, Interim Report, 12.5.2023 at 9:00 Kamux Corporation’s Interim Report for January 1—March 31, 2023: Kamux’s revenue decreased and adjusted operating profit decreased significantly This is a summary of Kamux Corporation’s Interim Report for January 1—March 31, 2023. The complete report is attached to this release and is also available at the company website at kamux.com . The figures in parentheses refer to the comparison period, i.e., the same period in the previous year, unless stated otherwise. January–March in brief · Revenue

First quarter report Q1-2023

· Study 0205 is progressing, with last patient expected in Q3 · Protocol finalized for study 0202, ready for submission in Q2 · Good progress with the commercialization strategy Cessatech A/S (“Cessatech” or the “Company”) today releases its results for the period 1 January – 31 March 2023. The first quarter report is available as an attached document to this press release and on www.cessatech.com under Investor/Filings & Reports. The Company is progressing well with planned activities, finalization of recruitment of pivotal study 0205 is expected in the third quarter of 2023 (a

Implantica publishes Interim Report January – March 2023 (Q1)

RefluxStop™ - Designed for a Revolution in the Care of Acid RefluxSignificant events in the first quarter of 2023 · RefluxStop™ is currently being launched in Scandinavia, with Ersta Hospital and Sundsvall Sjukhus in Sweden, the first centers committing to join our registry study. · Validated clinical data collection continues for RefluxStop™ with AKH Vienna presenting their results on their first RefluxStop™ patients at the Finnish Gastro Days Congress in Helsinki. · The first RefluxStop™ surgeries have been performed in Spain as we continue to prepare for the public tender

Irisity AB (publ) reports a good start of the year

Irisity AB (publ) reports a good start of the year.   CEO comments first quarter:   During the first quarter, we saw an improvement in net sales compared to the last two quarters, which were impacted by delays in our major project. Net sales during Q1 amounted to 27.5 MSEK which is an improvement to the 12.5 MSEK we reported in Q4 2022 and 13.3 MSEK in Q3 2022. The gross margin strengthened to 83.8 percent (77.0) and the monthly recurring income (MRR) amounted to 4.4 MSEK which is in line with the previous quarter (4.4).   Our EBITDA amounted to SEK -5.5 million (-4.8)

YIT recognised as the ideal construction industry employer for engineering students for the fifth consecutive year

YIT Corporation Press release 12 May 2023 at 9:00 a.m.Engineering students have ranked YIT as the most ideal construction industry employer in Universum’s Student Survey 2023 for the fifth consecutive time. On the ranking list of ideal technology industry employers, YIT reached fifth place. A total of 3,226 engineering students responded to the survey. YIT has also been ranked as the ideal construction industry employer among highly educated professionals in Universum’s Professionals Survey for three consecutive years. YIT will provide summer jobs and internships for about 600 young

Oneflow interim report Q1 2023: Executing according to plan in a turbulent market

Press release12 May 2023 Oneflow publishes its interim report for the first quarter of 2023: · Net sales increased 50% to MSEK 21.7 (14.5). Share of Net sales outside Sweden increased to 28% (22) with paying users in 32 countries. · EBIT was MSEK -23.5 (-11.0), with an EBIT margin of -108% (-75). · Basic earnings per share amounted to SEK -0.91 (-0.64) and diluted to SEK -0.91 (-0.64). · Total ARR YoY increased 52% to MSEK 99.6 (65.7).  · Net New ARR for the first quarter increased 4% to MSEK 9.0 (8.6). · Total cash and cash equivalents amounted to MSEK 188,035 (24,

There are no items matching the current filter
There are no more items matching the current filter
Back to top